Impact of Financial Incentives

Description

This trial will look at the impact of clinic-level financial incentives to improve provider communication and increase HPV vaccine uptake. Some clinics will receive communication training. Other clinics will receive the same training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.

Conditions

Human Papilloma Virus

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial will look at the impact of clinic-level financial incentives to improve provider communication and increase HPV vaccine uptake. Some clinics will receive communication training. Other clinics will receive the same training and a clinic-level financial incentive program with a monthly data feedback report to increase HPV vaccine uptake.

The Impact of Clinic-level Financial Incentives on HPV Vaccine Communication and Uptake

Impact of Financial Incentives

Condition
Human Papilloma Virus
Intervention / Treatment

-

Contacts and Locations

Chapel Hill

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599-7590

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * less than 72% HPV vaccine initiation rate,
  • * greater than or equal to 50 patients ages 9-12
  • * greater than or equal to 2 HPV vaccine providers
  • * no clinic or provider-level financial incentive programs to increase system, clinic, or provider HPV vaccination rates among patients aged 9-12 in the past two years, and
  • * no HPV vaccine provider communication trainings in the past six months.
  • * are between the ages of 9-12 years at baseline and
  • * are attributed to a participating clinic at 12- or 24-month follow-up.
  • * do not provide HPV vaccine to children ages 9-12
  • * have a specialty other than pediatrics or family medicine
  • * had an HPV vaccine-specific financial incentive program in the past two years
  • * had a formal HPV vaccine communication training in the past 6 months
  • * had an HPV initiation rate greater than 72$
  • * had fewer than 49 patients aged 9-12
  • * had 1 or fewer HPV vaccine providers
  • * are not between the ages of 9-12 years at baseline
  • * are not attributed to a participating clinic at 12- or 24-month follow-up

Ages Eligible for Study

9 Years to 12 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

UNC Lineberger Comprehensive Cancer Center,

Justin G Trogdon, PhD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill

Study Record Dates

2026-08-31